Humanwell Healthcare Group Co Ltd banner

Humanwell Healthcare Group Co Ltd
SSE:600079

Watchlist Manager
Humanwell Healthcare Group Co Ltd Logo
Humanwell Healthcare Group Co Ltd
SSE:600079
Watchlist
Price: 19.21 CNY 3.28% Market Closed
Market Cap: ¥31.4B

EV/FCFF

20.1
Current
46%
Cheaper
vs 3-y average of 37.5

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
20.1
=
Enterprise Value
¥35.5B
/
Free Cash Flow to Firm
¥1.8B

Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.

EV/FCFF
20.1
=
Enterprise Value
¥35.5B
/
Free Cash Flow to Firm
¥1.8B

Valuation Scenarios

Humanwell Healthcare Group Co Ltd is trading below its 3-year average

If EV/FCFF returns to its 3-Year Average (37.5), the stock would be worth ¥35.81 (86% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+90%
Average Upside
68%
Scenario EV/FCFF Value Implied Price Upside/Downside
Current Multiple 20.1 ¥19.21
0%
3-Year Average 37.5 ¥35.81
+86%
5-Year Average 38.3 ¥36.53
+90%
Industry Average 30.7 ¥29.29
+52%
Country Average 28.8 ¥27.48
+43%

Forward EV/FCFF
Today’s price vs future free cash flow to firm

Not enough data available to calculate forward EV/FCFF

Peer Comparison

All Multiples
EV/FCFF
P/E
All Countries
Close
Market Cap EV/FCFF P/E
CN
Humanwell Healthcare Group Co Ltd
SSE:600079
31.4B CNY 20.1 16.9
US
Eli Lilly and Co
NYSE:LLY
804.2B USD 153 42.6
US
Johnson & Johnson
NYSE:JNJ
547.4B USD 29.4 26.3
CH
Roche Holding AG
SIX:ROG
248.4B CHF 26.4 20.1
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP 35.4 28
US
Merck & Co Inc
NYSE:MRK
274.6B USD 24.7 15
CH
Novartis AG
SIX:NOVN
216.3B CHF 19.6 20.7
IE
Endo International PLC
LSE:0Y5F
244.4B USD 1 486.8 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 44.6 11.8
US
Pfizer Inc
NYSE:PFE
149.3B USD 22.1 19.6
US
Bristol-Myers Squibb Co
NYSE:BMY
115.9B USD 12 17.2
P/E Multiple
Earnings Growth PEG
CN
Humanwell Healthcare Group Co Ltd
SSE:600079
Average P/E: 21.8
16.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
42.6
32%
1.3
US
Johnson & Johnson
NYSE:JNJ
26.3
8%
3.3
CH
Roche Holding AG
SIX:ROG
20.1
14%
1.4
UK
AstraZeneca PLC
LSE:AZN
28
25%
1.1
US
Merck & Co Inc
NYSE:MRK
15
14%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.6
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
17.2
16%
1.1

Market Distribution

In line with most companies in China
Percentile
40th
Based on 4 731 companies
40th percentile
20.1
Low
0 — 14.5
Typical Range
14.5 — 57
High
57 —
Distribution Statistics
China
Min 0
30th Percentile 14.5
Median 28.8
70th Percentile 57
Max 307 555.7

Humanwell Healthcare Group Co Ltd
Glance View

Market Cap
31.4B CNY
Industry
Pharmaceuticals

In the rapidly evolving landscape of the Chinese pharmaceutical industry, Humanwell Healthcare Group Co Ltd. stands as a multifaceted player with its roots deeply embedded in both innovation and tradition. Founded in Wuhan, Humanwell has cultivated a robust portfolio that extends beyond the manufacture and distribution of pharmaceuticals, marking its presence in fields like anesthetics, reproductive health products, and specialty chemicals. Anchoring its operations is a commitment to research and development, investing significantly in new technologies and drug formulations. Humanwell leverages its extensive manufacturing capabilities and adheres to rigorous quality controls, enabling it to efficiently produce and market a diverse array of products across domestic and international markets. The company’s financial structure is bolstered by a savvy integration of its capabilities and strategic partnerships, enhancing both its market reach and product offerings. With subsidiaries spread across different continents, Humanwell taps into the lucrative supply chains of the healthcare sector, accentuating its revenue streams. Through strategic acquisitions and partnerships, the company has invested in expanding its global footprint, enhancing its competitive prowess. This tactical expansion, coupled with a keen focus on understanding and fulfilling consumer needs, allows Humanwell Healthcare not only to sustain a strong financial performance but also to play a pivotal role in shaping the future of the healthcare market in China and beyond.

Intrinsic Value
30.38 CNY
Undervaluation 37%
Intrinsic Value
Price ¥19.21
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett